Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 2; referees: 2 approved]
Background: With the availability of direct acting antiviral treatment for hepatitis C (HCV), HIV and HCV co-infected patients show comparable treatment responses to HCV-monoinfected patients. An 8-week course of sofosbuvir/ledipasvir (SOF/LDV) is highly effective for the treatment of HCV genotype 1...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2018-09-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/6-620/v2 |
| _version_ | 1818137557177729024 |
|---|---|
| author | Onyema Ogbuagu Ritche Hao Michael Virata Merceditas S. Villanueva Maricar Malinis |
| author_facet | Onyema Ogbuagu Ritche Hao Michael Virata Merceditas S. Villanueva Maricar Malinis |
| author_sort | Onyema Ogbuagu |
| collection | DOAJ |
| description | Background: With the availability of direct acting antiviral treatment for hepatitis C (HCV), HIV and HCV co-infected patients show comparable treatment responses to HCV-monoinfected patients. An 8-week course of sofosbuvir/ledipasvir (SOF/LDV) is highly effective for the treatment of HCV genotype 1 infection in treatment-naïve mono-infected patients with HCV viral loads <6 million IU/ml. There is limited data on the efficacy of this 8-week HCV treatment regimen in HIV-infected individuals with similar viral loads. Methods: The study was a retrospective review of HIV-infected adults coinfected with HCV genotype 1 for whom an 8-week course of SOF/LDV was prescribed by providers at two clinics in the Yale-New Haven Health system from November 1, 2014 until April 30, 2016. Treatment efficacy was assessed as the proportion of treatment initiators who achieved a sustained virologic response 12 weeks after completion of therapy (SVR 12). Results: Nineteen patients met study eligibility criteria and included 14 men (74%); and 12 African-Americans (63%). All patients were on antiretroviral therapy with fully suppressed HIV viral loads and were HCV treatment-naïve. All patients had pre-treatment HCV viral loads <6 million IU/mL. Eighteen patients (95%) completed HCV treatment. Overall, SVR 12 was 95%, with 1 treament failure occurring due to suboptimal adherence. Conclusion: Among our HIV-infected patient cohort with HCV genotype 1 infection, 95% of those treated with an 8 week course of SOF/LDV achieved SVR 12. This is comparable to the efficacy of the same treatment regimen in patients without HIV infection. This study lends proof of concept to the use of shorter course SOF/LDV treatment for HIV-HCV genotype 1 coinfected patients with viral loads <6 million IU/ml. Larger studies are indicated to validate our findings. |
| first_indexed | 2024-12-11T09:58:11Z |
| format | Article |
| id | doaj.art-805a154e230042ae872ba033388d8c3f |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-11T09:58:11Z |
| publishDate | 2018-09-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-805a154e230042ae872ba033388d8c3f2022-12-22T01:12:12ZengF1000 Research LtdF1000Research2046-14022018-09-01610.12688/f1000research.11397.217847Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 2; referees: 2 approved]Onyema Ogbuagu0Ritche Hao1Michael Virata2Merceditas S. Villanueva3Maricar Malinis4Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, 06510, USADepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, 06510, USADepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, 06510, USADepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, 06510, USADepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, 06510, USABackground: With the availability of direct acting antiviral treatment for hepatitis C (HCV), HIV and HCV co-infected patients show comparable treatment responses to HCV-monoinfected patients. An 8-week course of sofosbuvir/ledipasvir (SOF/LDV) is highly effective for the treatment of HCV genotype 1 infection in treatment-naïve mono-infected patients with HCV viral loads <6 million IU/ml. There is limited data on the efficacy of this 8-week HCV treatment regimen in HIV-infected individuals with similar viral loads. Methods: The study was a retrospective review of HIV-infected adults coinfected with HCV genotype 1 for whom an 8-week course of SOF/LDV was prescribed by providers at two clinics in the Yale-New Haven Health system from November 1, 2014 until April 30, 2016. Treatment efficacy was assessed as the proportion of treatment initiators who achieved a sustained virologic response 12 weeks after completion of therapy (SVR 12). Results: Nineteen patients met study eligibility criteria and included 14 men (74%); and 12 African-Americans (63%). All patients were on antiretroviral therapy with fully suppressed HIV viral loads and were HCV treatment-naïve. All patients had pre-treatment HCV viral loads <6 million IU/mL. Eighteen patients (95%) completed HCV treatment. Overall, SVR 12 was 95%, with 1 treament failure occurring due to suboptimal adherence. Conclusion: Among our HIV-infected patient cohort with HCV genotype 1 infection, 95% of those treated with an 8 week course of SOF/LDV achieved SVR 12. This is comparable to the efficacy of the same treatment regimen in patients without HIV infection. This study lends proof of concept to the use of shorter course SOF/LDV treatment for HIV-HCV genotype 1 coinfected patients with viral loads <6 million IU/ml. Larger studies are indicated to validate our findings.https://f1000research.com/articles/6-620/v2HIV Infection & AIDS: Clinical |
| spellingShingle | Onyema Ogbuagu Ritche Hao Michael Virata Merceditas S. Villanueva Maricar Malinis Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 2; referees: 2 approved] F1000Research HIV Infection & AIDS: Clinical |
| title | Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 2; referees: 2 approved] |
| title_full | Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 2; referees: 2 approved] |
| title_fullStr | Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 2; referees: 2 approved] |
| title_full_unstemmed | Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 2; referees: 2 approved] |
| title_short | Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 2; referees: 2 approved] |
| title_sort | efficacy of an 8 week course of sofosbuvir and ledipasvir for the treatment of hcv infection in selected hiv infected patients version 2 referees 2 approved |
| topic | HIV Infection & AIDS: Clinical |
| url | https://f1000research.com/articles/6-620/v2 |
| work_keys_str_mv | AT onyemaogbuagu efficacyofan8weekcourseofsofosbuvirandledipasvirforthetreatmentofhcvinfectioninselectedhivinfectedpatientsversion2referees2approved AT ritchehao efficacyofan8weekcourseofsofosbuvirandledipasvirforthetreatmentofhcvinfectioninselectedhivinfectedpatientsversion2referees2approved AT michaelvirata efficacyofan8weekcourseofsofosbuvirandledipasvirforthetreatmentofhcvinfectioninselectedhivinfectedpatientsversion2referees2approved AT merceditassvillanueva efficacyofan8weekcourseofsofosbuvirandledipasvirforthetreatmentofhcvinfectioninselectedhivinfectedpatientsversion2referees2approved AT maricarmalinis efficacyofan8weekcourseofsofosbuvirandledipasvirforthetreatmentofhcvinfectioninselectedhivinfectedpatientsversion2referees2approved |